Elritercept (KER-050 / TAK-226): A Comprehensive Profile

1. Introduction to Elritercept (KER-050 / TAK-226)

Elritercept, also identified by the development codes KER-050 and TAK-226, is an investigational therapeutic agent currently under clinical evaluation.[1] Structurally, it is engineered as a fusion protein. This protein combines a modified extracellular domain of the human activin receptor type IIA (ActRIIA) with the Fc (fragment crystallizable) region of human immunoglobulin G1 (IgG1).[3] Functionally, elritercept acts as a ligand trap, specifically modulating signaling pathways mediated by ActRIIA.[1] Its Chemical Abstracts Service (CAS) number is 2727114-26-1, and its FDA Unique Ingredient Identifier (UNII) is ZNC37E4KAK.[2]

The development of elritercept was initiated by Keros Therapeutics, Inc..[6] Recognizing its therapeutic potential, Takeda entered into a significant global license agreement with Keros, effective January 2025. This agreement grants Takeda exclusive rights for the development, manufacturing, and commercialization of elritercept worldwide, excluding mainland China, Hong Kong, and Macau.[1] The substantial upfront payment of $200 million from Takeda to Keros, coupled with potential future milestones, highlights the perceived value and strategic importance of elritercept within the hematology and oncology landscape.[1] This level of investment from a major pharmaceutical entity like Takeda suggests strong confidence in elritercept's potential, likely based on promising early-phase clinical data and its capacity to address significant unmet medical needs in its target indications. Takeda has explicitly identified elritercept as a key addition to its oncology pipeline and a potential driver for future growth.[7]

Elritercept is primarily being investigated for the treatment of hematologic disorders characterized by cytopenias, specifically anemia (low red blood cell count) and thrombocytopenia (low platelet count). The main target indications are Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF).[1]

2. Mechanism of Action

Elritercept exerts its therapeutic effect by modulating signaling within the Transforming Growth Factor-beta (TGF-β) superfamily, a group of proteins crucial for regulating numerous biological processes, including hematopoiesis (blood cell formation).[4]

Targeting TGF-β Superfamily Ligands: Elritercept functions as a "ligand trap." It is specifically engineered to bind and neutralize certain members of the TGF-β superfamily. Its primary target is Activin A, but it also inhibits Activin B, Growth Differentiation Factor 8 (GDF-8, also known as myostatin), and GDF-11.[4] These ligands normally bind to cell surface receptors, including ActRIIA, to regulate cell growth, differentiation, and function.

Receptor Modulation: By binding to these ligands, elritercept prevents them from interacting with their natural receptors, particularly ActRIIA.[1] This effectively inhibits the downstream signaling pathways activated by these ligands.

Rebalancing Hematopoietic Signaling: In conditions like MDS and MF, signaling pathways within the bone marrow are often dysregulated. Overactivity of ligands like Activin A is thought to contribute significantly to ineffective hematopoiesis – the impaired production and maturation of blood cells – which is a hallmark of these diseases.[4] Activin A, for example, is known to suppress the later stages of red blood cell development (erythropoiesis). By trapping Activin A and related ligands, elritercept aims to reduce these inhibitory signals and restore a more balanced signaling environment within the bone marrow, potentially involving the interplay between activin and bone morphogenetic protein (BMP) pathways.[13]

Promotion of Erythropoiesis and Thrombopoiesis: The net effect of inhibiting these suppressive signals is the promotion of blood cell production. Elritercept has demonstrated the ability to stimulate both erythropoiesis (red blood cell production) and thrombopoiesis (platelet production).[4] Evidence from preclinical and early clinical studies suggests that it acts on both early-stage progenitor cells and the later stages of maturation for both red blood cells and platelets.[4] This dual-lineage activity is a key feature of elritercept's mechanism. Unlike other agents targeting the TGF-β pathway, such as luspatercept and sotatercept (which primarily impact erythropoiesis), elritercept's ability to also stimulate platelet production was observed in preclinical models and confirmed in Phase 1 human studies.[4] This broader activity stems from its specific profile of binding multiple ligands within the TGF-β superfamily and could offer a therapeutic advantage in MDS and MF, where patients often suffer from both anemia and thrombocytopenia.

Potential Ancillary Effects: Beyond directly stimulating blood cell production, elritercept may exert other beneficial effects. Preclinical data hinted at improvements in iron utilization and a reduction in inflammation, both relevant to the underlying pathology of MDS.[5] Phase 1 data in healthy volunteers showed effects on bone turnover markers (increases in bone formation marker BSAP, decreases in resorption marker CTX).[17] Additionally, Phase 2 results in MDS patients showed rapid decreases in ferritin and hepcidin, suggesting improved iron homeostasis.[18] Effects on myocardial strain have also been hypothesized.[13]

The therapeutic strategy behind elritercept focuses on correcting the fundamental problem of ineffective hematopoiesis in MDS and MF.[5] By promoting the differentiation and maturation of blood cell progenitors [4], it aims to address the root cause of the cytopenias, distinguishing it from therapies that primarily stimulate the proliferation of existing mature cells or their late precursors.

3. Preclinical Evidence

The preclinical development of elritercept involved studies using a research form designated RKER-050.[4] These studies provided the foundational evidence for its mechanism of action and therapeutic potential.

In vivo experiments in both healthy and diseased rodent models consistently showed that RKER-050 administration led to increased production of both red blood cells and platelets.[4] This dual hematopoietic effect was further supported by in vitro studies demonstrating that RKER-050 promoted the differentiation of progenitor cells across both early and terminal stages of erythropoiesis and thrombopoiesis.[4] Additionally, in a murine model specifically designed to mimic myelofibrosis, RKER-050 was shown to promote erythropoiesis.[5]

Some preclinical data also suggested potential benefits related to iron metabolism, indicating that RKER-050 might improve iron utilization.[5]

These consistent preclinical findings, particularly the demonstration of stimulating both red blood cell and platelet lineages, were crucial. They provided strong support for the hypothesis that elritercept could address the multi-lineage cytopenias frequently observed in MDS and MF by targeting the underlying ineffective hematopoiesis. This preclinical proof-of-concept directly informed the design of subsequent clinical trials in humans.[4]

4. Clinical Development Program

Elritercept (KER-050) has progressed through Phase 1 and Phase 2 clinical trials, with a Phase 3 trial currently underway.

4.1. Phase 1 Study (Healthy Volunteers - ACTRN12619000318189)

• Design and Objectives: This first-in-human study was a randomized, double-blind, placebo-controlled trial conducted in Australia. It involved 48 healthy postmenopausal women and consisted of two parts: a single ascending dose (SAD) part (doses 0.05, 0.5, 1.5, 4.5 mg/kg SC) and a multiple ascending dose (MAD) part (0.75 mg/kg SC every 4 weeks for 2 doses). The primary objective was to assess the safety and tolerability of elritercept. Secondary objectives included evaluating its pharmacokinetics (PK) and pharmacodynamic (PD) effects on markers of hematopoiesis and activin inhibition.[4]
• Pharmacokinetics (PK): Following single subcutaneous doses, serum concentrations of elritercept increased in a dose-proportional manner. Peak concentrations (Cmax) were typically reached between 4.5 and 6 days post-dose. The mean elimination half-life was approximately 12 days, supporting the potential for dosing every 4 weeks (Q4W). PK parameters observed after multiple doses were comparable to those after a single dose.[4]
• Pharmacodynamics (PD): Elritercept administration led to rapid, sustained, and dose-dependent increases in markers of red blood cell production (reticulocytes, red blood cells, hemoglobin) and platelet counts.[4] These effects were observed without detrimental changes in white blood cell counts (neutrophils, lymphocytes).[4] The pattern and duration of these changes were consistent with the stimulation of both early and late stages of hematopoiesis.[4] Additionally, dose-dependent increases in the bone formation marker BSAP and decreases in the bone resorption marker CTX were noted, along with increases in adiponectin and decreases in leptin, suggesting effects on bone and fat metabolism consistent with activin inhibition.[17] This early human data provided confirmation of the dual hematopoietic stimulation (erythroid and platelet lineages) observed preclinically, strengthening the rationale for testing in MDS/MF.[4]
• Safety and Tolerability: Elritercept was reported to be generally well tolerated across all tested dose levels. No dose-limiting toxicities (DLTs), severe adverse events (AEs), or serious adverse events (SAEs) related to the drug were observed. There were also no clinically significant changes in safety laboratory parameters.[4] The most frequently reported treatment-emergent adverse events (TEAEs) overall included headache and upper respiratory tract infections (URIs). Dose-dependent increases in hemoglobin were also reported as TEAEs in the higher dose groups.[14] The favorable safety profile established in this initial human study was a critical step, supporting the decision to advance elritercept into clinical trials involving patient populations.[4]

4.2. Phase 2 Studies (Patient Populations)

4.2.1. Myelodysplastic Syndromes (MDS - NCT04419649 / KER050-MD-201)

• Design and Population: This ongoing Phase 2, open-label, ascending dose study enrolled patients with very low-, low-, or intermediate-risk MDS (LR-MDS) suffering from anemia. The study included cohorts of both transfusion-dependent (TD) and non-transfused (NT) patients.[23]
• Efficacy Results (as of Dec 2024 ASH update):
• Erythroid Response: Elritercept demonstrated significant erythroid activity. In the transfusion independence (TI)-evaluable population (n=63), 41.3% achieved RBC-TI for ≥8 weeks within the first 24 weeks of treatment. This response proved durable, with 61.5% of these responders maintaining TI for ≥24 weeks over a 48-week period. The median duration of TI had not been reached at the data cutoff, with over 60% of responders having ongoing TI, some exceeding one year.[11] Responses were seen even in patients with high transfusion burden (HTB; ≥4 RBC units/8 weeks), where 34.8% achieved TI ≥8 weeks.[11] Efficacy was particularly notable in patients with baseline erythropoietin (EPO) levels <500 U/L, where 50% achieved TI ≥8 weeks.[11] In the non-transfused cohort (n=15), 86.7% achieved a hematologic improvement-erythroid (HI-E) response, with 73.3% maintaining mean hemoglobin levels ≥11 g/dL for at least 8 weeks. These responses were also durable.[18] The breadth of response across different patient subgroups (TD/NT, HTB/LTB, RS+/RS-) suggests elritercept may benefit a wide range of LR-MDS patients with anemia.[11]
• Quality of Life (QoL) / Fatigue: Improvements in patient-reported outcomes correlated with hematologic response. Patients achieving durable TI (≥24 weeks) showed greater improvements in FACT-An scores compared to non-responders.[11] In the NT cohort, 60% experienced a clinically meaningful improvement in fatigue (MCID on FACIT-Fatigue) by week 12.[18] This link between durable erythroid response and improved patient well-being highlights the clinical relevance of the observed efficacy.[11]
• Iron Homeostasis/Inflammation: Treatment with elritercept led to rapid and sustained decreases in serum ferritin and hepcidin levels in NT patients.[18] This suggests a potential beneficial effect on iron metabolism and possibly inflammation, which are often dysregulated in MDS and contribute to anemia. This finding aligns with preclinical hypotheses [5] and may represent an additional therapeutic benefit beyond erythropoiesis stimulation.
• Safety: The safety profile in MDS patients was generally consistent with previous findings. The most common TEAEs (≥15%) reported in the overall safety population (n=87) were diarrhea, fatigue, dyspnea, dizziness, COVID-19, nausea, and anemia.[11] Six fatal TEAEs occurred during the trial, but all were assessed by investigators as unrelated to elritercept treatment.[19] Importantly, no patients progressed to acute myeloid leukemia (AML) during the observation period.[11]

4.2.2. Myelofibrosis (MF - RESTORE - NCT05037760)

• Design and Population: This ongoing Phase 2, open-label study evaluates elritercept as monotherapy or in combination with the JAK inhibitor ruxolitinib in patients with MF and associated anemia. Participants included those already on ruxolitinib, those who had failed it, or those ineligible for it.[11]
• Efficacy Results (as of Dec 2024 ASH update):
• Anemia/Transfusion Burden: Elritercept showed potential to address MF-associated anemia. Increases in hemoglobin (≥1.0 g/dL) were observed in 51.7% of evaluable non-TD patients across both monotherapy and combination arms within the first 24 weeks.[15] Among TD patients (n=41), 39% experienced a ≥50% reduction in transfusion burden, and 24% achieved TI within the first 24 weeks.[15] In the combination arm subgroup receiving elritercept ≥3 mg/kg, 62.5% had ≥50% transfusion reduction, and 37.5% achieved TI.[19]
• Platelets: Platelet counts were generally stable or improved, even in patients with baseline thrombocytopenia, across both treatment arms.[13]
• Spleen Volume: Reductions in spleen volume were observed at week 24. Overall, 40% of evaluable patients achieved a ≥10% reduction.[13] In the combination arm (≥3mg/kg), 88% experienced some reduction.[11]
• Symptoms: Improvements in MF symptoms, measured by the Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF-TSS), were seen in over two-thirds of patients with significant baseline symptoms at week 24.[13] Five patients achieved a ≥50% reduction in TSS.[11] These results suggest elritercept may offer benefits beyond anemia control, potentially impacting key disease manifestations like splenomegaly and symptom burden.[11]
• Safety: Elritercept was generally well-tolerated in MF patients, both as monotherapy and combined with ruxolitinib. The most common TEAEs (≥15%) were thrombocytopenia (20.5% overall) and diarrhea (19.2% overall).[11] Grade ≥3 thrombocytopenia occurred in 16.4% of patients.[15] Four fatal TEAEs were reported, all deemed unrelated to elritercept.[11] One DLT (Hb increase ≥2.0 g/dL) occurred in the monotherapy arm.[15] The data suggest elritercept can be safely combined with ruxolitinib and may help mitigate JAK inhibitor-associated cytopenias while potentially adding to spleen and symptom control.[11] Part 2 of the trial is ongoing at the recommended Phase 2 dose (RP2D) of 3.75 mg/kg.[15]

4.3. Phase 3 Study (MDS - RENEW - NCT06499285 / KER-050-D301)

• Design and Population: The RENEW trial is a pivotal Phase 3, global, randomized (2:1), double-blind, placebo-controlled study designed to definitively evaluate elritercept's efficacy and safety.[9] It aims to enroll approximately 255 to 350 adult participants with transfusion-dependent anemia associated with very low-, low-, or intermediate-risk MDS (per IPSS-R) who are refractory to, ineligible for, or have relapsed after ESA therapy.[9] Participants are stratified by ring sideroblast (RS) status and baseline transfusion burden (Low Transfusion Burden vs. High Transfusion Burden).[31]
• Intervention: Participants receive either elritercept or a matching placebo via subcutaneous injection every 4 weeks (Q4W).[31] The study includes a primary treatment phase, a secondary phase, and an extension phase, followed by safety and long-term follow-up.[31]
• Endpoints: The primary endpoint is the proportion of participants achieving RBC transfusion independence (RBC-TI) lasting for at least 8 consecutive weeks during the first 24 weeks of the double-blind treatment period.[31] Key secondary endpoints are comprehensive, assessing various measures of erythroid response (TI ≥8 weeks anytime, TI ≥12 weeks, duration of TI, Hb increase ≥1.0 or ≥1.5 g/dL, HI-E response per IWG 2006/2018 criteria, time to first transfusion, reduction in transfusion burden), safety and tolerability (AEs, SAEs, discontinuations), patient-reported outcomes (fatigue via FACIT-F, QoL via EORTC QLQ-C30), and markers of disease biology (BM blasts, cytogenetics, serum ferritin).[31]
• Status and Locations: The trial is actively recruiting participants (as of Feb 2025) across multiple international sites, including the United States, Europe (Bulgaria, Czechia, France, Germany, Hungary, Ireland, Italy, Poland, Spain, Sweden), and Australia.[23]
• Significance: As a large, randomized, placebo-controlled Phase 3 study, RENEW is designed to provide the high-level evidence required for regulatory submissions. Its success is crucial for establishing elritercept as a potential new standard of care for anemia in LR-MDS patients with limited treatment options.[9]

4.4. Summary Table of Key Clinical Trials

Trial ID (NCT/ACTRN)	Phase	Condition(s)	Status	Est. Enrollment	Key Intervention(s)	Primary Endpoint	Key Results Summary / Objective
ACTRN12619000318189	Phase 1	Healthy Postmenopausal Volunteers	Completed	48	Elritercept (SAD/MAD) vs Placebo	Safety & Tolerability	Generally well-tolerated; PK supported Q4W dosing; Dose-dependent ↑ in RBCs, Hb, Platelets 4
NCT04419649 (KER050-MD-201)	Phase 2	LR-MDS with Anemia (TD & NT)	Recruiting	~110	Elritercept (Open-label, Asc Dose)	Safety & Tolerability (Part 1); HI-E Response (Part 2)	Durable TI/HI-E responses in TD/NT pts, improved fatigue/QoL, ↓Ferritin/Hepcidin; Generally well-tolerated 11
NCT05037760 (RESTORE)	Phase 2	Myelofibrosis (MF) with Anemia	Recruiting	~110	Elritercept +/- Ruxolitinib	Safety & Tolerability (Part 1); Dose Confirmation (Part 2)	Improved Hb/transfusion burden, stable/improved platelets, spleen/symptom reduction observed; Generally well-tolerated 11
NCT06499285 (RENEW)	Phase 3	TD LR-MDS (ESA-refractory/ineligible)	Recruiting	~255-350	Elritercept SC Q4W vs Placebo	Proportion achieving RBC-TI ≥8 weeks during first 24 weeks 31	Pivotal study to confirm efficacy/safety for regulatory approval in LR-MDS anemia 9

Abbreviations: ACTRN=Australian New Zealand Clinical Trials Registry; AE=Adverse Event; AML=Acute Myeloid Leukemia; ASH=American Society of Hematology; BSAP=Bone-Specific Alkaline Phosphatase; CTX=C-Terminal Telopeptide; DLT=Dose-Limiting Toxicity; EHA=European Hematology Association; EMA=European Medicines Agency; EPO=Erythropoietin; ESA=Erythropoiesis-Stimulating Agent; EU=European Union; FACT-An=Functional Assessment of Cancer Therapy-Anemia; FACIT-F=Functional Assessment of Chronic Illness Therapy-Fatigue; FDA=Food and Drug Administration; GDF=Growth Differentiation Factor; Hb=Hemoglobin; HI-E=Hematologic Improvement-Erythroid; HTB=High Transfusion Burden; IgG1=Immunoglobulin G1; IH=Ineffective Hematopoiesis; IND=Investigational New Drug; IPSS-R=Revised International Prognostic Scoring System; IWG=International Working Group; JAK=Janus Kinase; LR-MDS=Lower-Risk Myelodysplastic Syndromes; LTB=Low Transfusion Burden; MAD=Multiple Ascending Dose; MCID=Minimal Clinically Important Difference; MDS=Myelodysplastic Syndromes; MF=Myelofibrosis; MF-SAF-TSS=Myelofibrosis Symptom Assessment Form Total Symptom Score; NCI=National Cancer Institute; NCT=National Clinical Trial; NT=Non-Transfused; ODD=Orphan Drug Designation; PD=Pharmacodynamics; PK=Pharmacokinetics; PMF=Primary Myelofibrosis; Post-ET MF=Post-Essential Thrombocythemia Myelofibrosis; Post-PV MF=Post-Polycythemia Vera Myelofibrosis; Q4W=Every 4 Weeks; QoL=Quality of Life; RBC=Red Blood Cell; RBC-TI=Red Blood Cell Transfusion Independence; RKER-050=Research form of Elritercept; RS=Ring Sideroblast; SAD=Single Ascending Dose; SAE=Serious Adverse Event; SC=Subcutaneous; SRC=Safety Review Committee; TD=Transfusion-Dependent; TEAE=Treatment-Emergent Adverse Event; TGF-β=Transforming Growth Factor-beta; TI=Transfusion Independence; URI=Upper Respiratory Tract Infection; US=United States.

5. Integrated Safety and Tolerability Profile

Across the clinical development program to date, elritercept has demonstrated a generally consistent and manageable safety profile in both healthy volunteers and patients with MDS or MF.[4]

In the Phase 1 study involving healthy postmenopausal women, elritercept was well tolerated up to the highest single dose tested (4.5 mg/kg) and with multiple doses (0.75 mg/kg Q4W x 2). No dose-limiting toxicities, severe AEs, or drug-related SAEs were reported.[4] The most common TEAEs were generally mild and included headache and URIs, with dose-dependent increases in hemoglobin also noted as an AE at higher doses.[14]

In the Phase 2 study in patients with LR-MDS (NCT04419649), elritercept continued to be generally well-tolerated. The most frequently reported TEAEs (≥15% incidence) included diarrhea, fatigue, dyspnea, dizziness, COVID-19, nausea, and anemia.[11] While six fatal TEAEs occurred, investigators deemed them unrelated to elritercept treatment.[19] No patients progressed to AML.[11] Dose modifications (delays or reductions) were sometimes necessary due to hemoglobin increases (an on-target effect), but hematologic responses were often maintained or regained despite these adjustments.[18]

In the Phase 2 RESTORE study in MF patients (NCT05037760), the safety profile was similar, with thrombocytopenia and diarrhea being the most common TEAEs (≥15%).[11] Grade 3 or higher thrombocytopenia was observed in 16.4% of patients, although overall platelet counts tended to stabilize or improve.[13] Four fatal TEAEs occurred, also deemed unrelated to elritercept.[11] A single DLT, an increase in hemoglobin >2.0 g/dL, was reported in the monotherapy arm, again reflecting the drug's erythropoietic activity.[15]

Overall, the safety data gathered thus far suggest a manageable profile. Gastrointestinal events (diarrhea, nausea) and fatigue appear relatively common across patient populations. Expected on-target pharmacodynamic effects, such as increases in hemoglobin, can manifest as AEs or even a DLT, necessitating careful monitoring and potential dose adjustments. Thrombocytopenia is notable in the MF population, likely reflecting the underlying disease and potential interaction with ruxolitinib, but the tendency for platelet counts to stabilize or improve is a positive observation.[13] The absence of related SAEs in Phase 1 and the determination that fatal TEAEs in Phase 2 were unrelated to the drug are encouraging, though continued vigilance in the ongoing Phase 3 trial is warranted.

6. Regulatory and Commercial Landscape

Elritercept has received certain regulatory designations aimed at facilitating its development for conditions with unmet medical needs. The FDA granted Fast Track designation for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk MDS.[8] Fast Track designation was also granted by the FDA for myelofibrosis.[30] This status acknowledges the potential of elritercept to address serious conditions and allows for more frequent interactions with the FDA, potentially expediting the development and review process.[8]

The Orphan Drug Designation (ODD) status for elritercept appears less clear based on the provided information. While some sources mention ODD for MDS [41], specific EMA documentation for the Phase 2 MDS trial (EudraCT 2021-001838-19) indicates that ODD was not designated for that specific indication within the Community at that time.[24] An EMA ODD identifier (EU/3/22/2458) exists, but its specific details were inaccessible in the provided materials.[44] No definitive confirmation of FDA ODD for MDS or MF, nor EMA ODD for MF, was found in the reviewed snippets.[39] Further clarification from regulatory agency databases or the developer would be needed to confirm the current ODD status in the US and EU for specific indications.

A major development in the commercial landscape occurred in late 2024/early 2025 with the finalization of an exclusive global licensing agreement between Keros Therapeutics and Takeda.[1] Takeda acquired the rights to develop, manufacture, and commercialize elritercept worldwide (excluding Greater China) for all indications.[7] This partnership provides Keros with substantial funding ($200M upfront plus potential milestones/royalties) and significantly de-risks the late-stage development and potential market launch by leveraging Takeda's extensive global infrastructure and expertise in oncology and hematology.[1] Takeda now leads the ongoing development efforts, including the pivotal Phase 3 RENEW trial.[1]

7. Conclusion and Future Perspectives

Elritercept (KER-050 / TAK-226) emerges as a promising investigational therapeutic targeting ineffective hematopoiesis in MDS and MF. As a modified ActRIIA ligand trap, it inhibits key negative regulators of blood cell production, notably Activin A, thereby promoting the maturation of both erythroid and platelet precursors.[1] This dual-lineage activity, supported by preclinical and Phase 1 data, differentiates it from other agents in its class.[4]

Phase 2 clinical trials have provided encouraging evidence of efficacy in patient populations. In LR-MDS, elritercept demonstrated the ability to induce durable transfusion independence and hemoglobin increases in a significant proportion of anemic patients, including those with high transfusion burdens, alongside improvements in fatigue and markers of iron homeostasis.[11] In MF, it showed potential to improve anemia (disease- or ruxolitinib-associated), stabilize/improve platelet counts, and provide broader benefits by reducing spleen volume and symptom burden, both as monotherapy and in combination with ruxolitinib.[11] Across these studies, elritercept has maintained a generally manageable safety profile.[4]

The ongoing pivotal Phase 3 RENEW trial (NCT06499285) in transfusion-dependent LR-MDS represents a critical step towards potential regulatory approval.[9] Positive results from this trial would solidify elritercept's role in addressing the significant unmet need for effective and durable anemia treatments in this patient group, particularly those who are ineligible for or refractory to ESAs.[5] Continued positive data from the Phase 2 RESTORE trial in MF could further establish its utility in managing cytopenias and other disease aspects in MF patients, including those on JAK inhibitor therapy.[13]

The strategic partnership with Takeda ensures robust support for late-stage development and global commercialization, significantly enhancing the probability of elritercept reaching patients if approved.[1] Future research will likely focus on confirming the long-term efficacy and safety, further elucidating its impact on disease progression, iron metabolism, and potentially bone health, and defining its optimal place in the treatment algorithms for MDS and MF.

Disclaimer:

This report is based on the synthesis of information from the provided research snippets.[1] It is intended for informational purposes only and does not constitute medical advice. The development status, trial results, and regulatory landscape are subject to change. Verification with primary sources and regulatory agencies is recommended for the most current information. Some referenced sources were inaccessible during the generation of this report.

Works cited

1. Elritercept - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 9, 2025, https://synapse.patsnap.com/drug/cfdd80e3d3b3438ba451571a5ca07111
2. Elritercept - Inxight Drugs - ncats, accessed May 9, 2025, https://drugs.ncats.io/drug/ZNC37E4KAK
3. Elritercept: A Promising Treatment for Myelofibrosis and Myelodysplastic Syndromes - Clinical trials, accessed May 9, 2025, https://clinicaltrials.eu/inn/elritercept/
4. Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial - PMC - PubMed Central, accessed May 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11758838/
5. Elritercept for Transfusion-Dependent Anemia in Lower-Risk MDS: A Trial in Progress, accessed May 9, 2025, https://www.bloodcancerstoday.com/post/elritercept-for-transfusion-dependent-anemia-in-lower-risk-mds-a-trial-in-progress
6. Keros Therapeutics Announces Effectiveness of Global License ..., accessed May 9, 2025, https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-effectiveness-global-license/
7. Takeda Enhances Oncology Pipeline with Elritercept via Keros Therapeutics License Deal, accessed May 9, 2025, https://synapse.patsnap.com/article/takeda-enhances-oncology-pipeline-with-elritercept-via-keros-therapeutics-license-deal
8. Takeda, Keros Enter Exclusive Elritercept Agreement - Contract Pharma, accessed May 9, 2025, https://www.contractpharma.com/breaking-news/takeda-keros-enter-exclusive-elritercept-agreement/
9. Keros Therapeutics considers sale amid investor pressure - Pharmaceutical Technology, accessed May 9, 2025, https://www.pharmaceutical-technology.com/news/keros-therapeutics-considers-sale-amid-investor-pressure/?
10. TAKEDA PHARMACEUTICAL CO LTD Form 6-K Current Event Report Filed 2024-12-13 - SECDatabase, accessed May 9, 2025, http://pdf.secdatabase.com/2387/0001395064-24-000172.pdf
11. Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association, accessed May 9, 2025, https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-presents-clinical-data-its-elritercept-ker/
12. Keros Therapeutics Reports Recent First Quarter 2025 Financial Results, accessed May 9, 2025, https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-reports-recent-first-quarter-2025-financial
13. Elritercept May Provide Clinically Meaningful Benefits for Patients ..., accessed May 9, 2025, https://ashpublications.org/ashclinicalnews/news/8249/Elritercept-May-Provide-Clinically-Meaningful
14. Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial | Blood Advances | American Society of Hematology, accessed May 9, 2025, https://ashpublications.org/bloodadvances/article/9/1/193/518289/Elritercept-a-modified-activin-receptor-IIA-ligand
15. RESTORE phase II results: Elritercept as monotherapy and in combination with ruxolitinib in MF - MPN Hub, accessed May 9, 2025, https://mpn-hub.com/medical-information/restore-phase-ii-results-elritercept-as-monotherapy-and-in-combination-with-ruxolitinib-in-mf
16. Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial - PubMed, accessed May 9, 2025, https://pubmed.ncbi.nlm.nih.gov/39437803/
17. Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers, accessed May 9, 2025, https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-initial-topline-results-phase-1/
18. Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial | Blood, accessed May 9, 2025, https://ashpublications.org/blood/article/144/Supplement%201/4591/533055/Hematologic-Improvement-and-Fatigue-Reduction-with
19. Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire, accessed May 9, 2025, https://www.globenewswire.com/news-release/2024/12/10/2994148/0/en/Keros-Therapeutics-Presents-Clinical-Data-from-its-Elritercept-Program-at-the-66th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html
20. Ruxolitinib Combinations in MPNs: Updates From ASH, accessed May 9, 2025, https://www.ajmc.com/view/ruxolitinib-combinations-in-mpns-updates-from-ash
21. accessed January 1, 1970, https.www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377123&isReview=true
22. Registration - ANZCTR, accessed May 9, 2025, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377123
23. EU Clinical Trials Register, accessed May 9, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001838-19/DE
24. EU Clinical Trials Register, accessed May 9, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001838-19/ES
25. A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes - National Cancer Institute, accessed May 9, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02457
26. accessed January 1, 1970, https.www.clinicaltrials.gov/study/NCT04419649
27. Error | ClinicalTrials.gov, accessed May 9, 2025, https://clinicaltrials.gov/study/NCT04419649
28. Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis - LarvolClin, accessed May 9, 2025, https://clin.larvol.com/trial-detail/NCT05037760
29. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT05037760
30. The Benefits of Elritercept for Myelofibrosis? - HealthTree, accessed May 9, 2025, https://healthtree.org/myelofibrosis/community/articles/ash-24-elritercept-for-myelofibrosis
31. The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW) - NCI, accessed May 9, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-00078
32. The Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia (RENEW) - NCI, accessed May 9, 2025, https://www.cancer.gov/clinicaltrials/NCI-2025-00078
33. 해외 바이오의약품 임상 현황, accessed May 9, 2025, https://www.kobia.kr/bbs/download.php?tbl=data05&no=6199
34. The Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia (RENEW) - NCI, accessed May 9, 2025, https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2025-00078
35. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06499285
36. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT06499285
37. accessed January 1, 1970, https://www.clinicaltrialsregister.eu/ctr-search/search?query=elritercept
38. New Drug For Anemia In MDS Patients - HealthTree for Myelodysplastic Syndromes, accessed May 9, 2025, https://healthtree.org/mds/community/articles/elritercept-for-mds-new-drug
39. New Drug Designations - March 2024 - PharmaShots, accessed May 9, 2025, https://pharmashots.com/17336/new-drug-designations-march-2024/
40. Which of these orphan drug designations is right for you? - TMC Pharma, accessed May 9, 2025, https://tmcpharma.com/fda-vs-ema-orphan-drug-designation/
41. What's New? | MDS Foundation, accessed May 9, 2025, https://www.mds-foundation.org/whats-new/?page=2
42. Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS, accessed May 9, 2025, https://www.rigel.com/news-media/press-releases/detail/406/rigel-announces-r289-granted-orphan-drug-designation-by-the
43. FDA Grants Orphan Drug Designation for MDS to Investigational CLEVER-1-Targeting Immunotherapy | Docwire News, accessed May 9, 2025, https://www.docwirenews.com/post/fda-grants-orphan-drug-designation-for-mds-to-investigational-clever-1-targeting-immunotherapy
44. accessed January 1, 1970, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3222458
45. Myelofibrosis - Blood Cancers Today, accessed May 9, 2025, https://www.bloodcancerstoday.com/disease-state/myelofibrosis
46. GERON CORPORATION, accessed May 9, 2025, https://s201.q4cdn.com/710325604/files/doc_financials/2024/ar/94cf9f17-7e1f-4396-a812-357f76447ca2.pdf
47. Pioneering LOX Inhibitors in Haematological Cancers - Evolution Capital, accessed May 9, 2025, https://www.eveq.com/wp-content/uploads/2025/03/SNT_Initiation_Report.pdf
48. MDS - Myelodysplastic Syndromes - Blood Cancers Today, accessed May 9, 2025, https://www.bloodcancerstoday.com/page/mds
49. 2024 Annual Report, accessed May 9, 2025, https://s201.q4cdn.com/710325604/files/doc_financials/2024/ar/Proxy-Statement-for-2025-Annual-Meeting-ARS-Annual-Report-as-filed-8APR2025.pdf
50. accessed January 1, 1970, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=YOUR_KEY_HERE